Comment
Author: Admin | 2025-04-28
Randomized clinical trial. JAMA. 2021;325(23):2348–56.Article CAS PubMed Google Scholar Ashina M, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–54.Article PubMed PubMed Central Google Scholar Lipton RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–77.Article CAS PubMed PubMed Central Google Scholar Hutchinson S, et al. Oral rimegepant 75 mg is safe and well tolerated in adults with migraine and cardiovascular risk factors: results of a multicenter, long-term, open-label safety study. Neurology 96 (S15):1995.Johnston K, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant—post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022;23(1):10.Article CAS PubMed PubMed Central Google Scholar Goadsby PJ, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–37.Article CAS PubMed Google Scholar Ailani J, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.Article CAS PubMed Google Scholar Schwedt TJ, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022;42(1):3–11.Article PubMed Google Scholar Boinpally R, et al. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial. Pain Manag. 2022;12(4):499–508.Article PubMed Google Scholar Pozo-Roisch P, et al. Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial. Headache, 2022. (in press).Croop R, et al. Intranasal zavegepant is effective and well tolerated for the acute treatment of migraine: a phase 2/3 dose-ranging clinical trial. Headache. 2021;61:104–5. Google Scholar Biohaven achieves positive topline results in pivotal phase 2/3 study of vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine [press release]. 2019, Biohaven Pharmaceuticals; biohavenpharma.com/investors/news-events/press-releases/12-17-2019: New Haven, CT.Mercer SE, et al. Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett. 2021;31: 127624.Article CAS PubMed Google Scholar Danysz W, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease—a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res. 2000;2(2–3):85–97.Article CAS PubMed Google Scholar Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15(2):361–70.Article CAS PubMed PubMed Central Google Scholar Shanmugam S, et al. Memantine ameliorates migraine headache. Ann Indian Acad Neurol. 2019;22(3):286–90.Article PubMed PubMed Central Google Scholar Kashipaza D, Emadi S. The effect of memantine on prophylaxis of chronic migraine headache. ARC Journal of Neuroscience. 2018;3(3):1–7. Google Scholar Noruzzadeh R, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Headache. 2016;56(1):95–103.Article PubMed Google Scholar Zhou T, Tang Y, Zhu H. Effectiveness and safety of memantine for headache: a meta-analysis of randomized controlled studies. Clin Neuropharmacol. 2022;45(3):40–4.Article CAS PubMed Google Scholar Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190–9.Article CAS PubMed PubMed Central Google Scholar Nesbitt AD, Leschziner GD,
Add Comment